EA200970816A1 - Новая лекарственная форма - Google Patents

Новая лекарственная форма

Info

Publication number
EA200970816A1
EA200970816A1 EA200970816A EA200970816A EA200970816A1 EA 200970816 A1 EA200970816 A1 EA 200970816A1 EA 200970816 A EA200970816 A EA 200970816A EA 200970816 A EA200970816 A EA 200970816A EA 200970816 A1 EA200970816 A1 EA 200970816A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new medicine
medicine form
dosage form
new
medicine
Prior art date
Application number
EA200970816A
Other languages
English (en)
Inventor
Аллан Джеймс Кларк
Ян Пол Конн
Саймон Ричард Хикс
Юй Ли
Сяолэй Ван
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39402661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970816(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970816A1 publication Critical patent/EA200970816A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Настоящее изобретение относится к новой лекарственной форме, способу получения лекарственной формы и применению лекарственной формы в медицине.
EA200970816A 2007-03-01 2008-02-28 Новая лекарственная форма EA200970816A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89226607P 2007-03-01 2007-03-01
PCT/EP2008/052429 WO2008104589A1 (en) 2007-03-01 2008-02-28 Novel dosage form

Publications (1)

Publication Number Publication Date
EA200970816A1 true EA200970816A1 (ru) 2009-12-30

Family

ID=39402661

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970816A EA200970816A1 (ru) 2007-03-01 2008-02-28 Новая лекарственная форма

Country Status (15)

Country Link
US (1) US20110020447A1 (ru)
EP (1) EP2131846A1 (ru)
JP (1) JP2010520173A (ru)
KR (1) KR20090130013A (ru)
CN (1) CN101674836A (ru)
AR (1) AR065528A1 (ru)
AU (1) AU2008220794A1 (ru)
BR (1) BRPI0808412A2 (ru)
CA (1) CA2679525A1 (ru)
CL (1) CL2008000597A1 (ru)
EA (1) EA200970816A1 (ru)
MX (1) MX2009009361A (ru)
PE (1) PE20081797A1 (ru)
TW (1) TW200902021A (ru)
WO (1) WO2008104589A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010023170A1 (en) * 2008-08-29 2010-03-04 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509413C (en) * 2002-12-20 2012-05-01 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
WO2008104589A1 (en) 2008-09-04
AU2008220794A1 (en) 2008-09-04
PE20081797A1 (es) 2009-01-25
TW200902021A (en) 2009-01-16
CL2008000597A1 (es) 2008-09-05
JP2010520173A (ja) 2010-06-10
KR20090130013A (ko) 2009-12-17
CN101674836A (zh) 2010-03-17
US20110020447A1 (en) 2011-01-27
CA2679525A1 (en) 2008-09-04
AR065528A1 (es) 2009-06-10
BRPI0808412A2 (pt) 2014-07-15
MX2009009361A (es) 2009-09-14
EP2131846A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA200802324A1 (ru) Новая форма введения рацекадотрила
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201171389A1 (ru) Лекарственная форма
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AU2011328009A8 (en) Compounds and methods for treating pain
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
EA201001639A1 (ru) Композиции и способы их получения и применения
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA201190312A1 (ru) Замещенные пиперидины
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)